---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-113204"
form_type: "8-K"
ticker: "KNSA"
cik: "0001730430"
company_name: "Kiniksa Pharmaceuticals International, plc"
filed_at: "2022-11-01T23:59:59+00:00"
generated_at: "2026-06-22T18:51:14.588976+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Kiniksa Q3 ARCALYST rev $33.4M, total rev $99.1M, net income $224.1M on tax benefit

## Summary
- ARCALYST net revenue $33.4M in Q3 2022; full-year guidance reaffirmed at $115-130M.
- Total revenue $99.1M, including $65.7M from vixarelimab license with Genentech.
- Net income $224.1M vs net loss $30.5M YoY; includes $177.4M tax benefit from valuation allowance release.
- Cash and equivalents $200.7M, no debt; expected to fund operations into at least 2025.
- RHAPSODY LTE data: rilonacept beyond 18 months reduced recurrence risk 98.2% (HR=0.018, p<0.0001).

## SEC filing metadata
- accession: 0001104659-22-113204
- form_type: 8-K
- ticker: KNSA
- cik: 0001730430
- company_name: Kiniksa Pharmaceuticals International, plc
- filed_at: 2022-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730430/000110465922113204/0001104659-22-113204-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730430/000110465922113204/tm2229208d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-113204
- JSON: https://secwatch.observer/filing/0001104659-22-113204.json
- Plain text: https://secwatch.observer/filing/0001104659-22-113204.txt

## Key facts
- Earnings Releases
  Kiniksa Pharmaceuticals International, plc reported Third Quarter 2022 results: revenue $99.1 million, net income $224.1 million.
  - Period: Third Quarter 2022
  - Revenue: $99.1 million
  - Net income: $224.1 million
  - Result: reported results
  source text: Total revenue for the third quarter of 2022 was $99.1 million, compared to $12.1 million for the third quarter of 2021. - Total revenue for the third quarter of 2022 included $33.4 million in ARCALYST net product revenue and $65.7 million in license and collaboration revenue from the vixarelimab global license agreement with Genentech. Kiniksa did not report license and collaboration revenue in the third quarter of 2021. · Total operating expenses for the third quarter of 2022 were $52.7 million, compared to $42.8 million for the third quarter of 2021. - Total operating expenses for the third quarter of 2022 included $4.6 million in collaboration expense. Kiniksa did not report collaboration expense in the third quarter of 2021. - Total operating expenses for the third quarter of 2022 included $6.0 million of non-cash, share-based compensation expense, compared to $6.2 million for third quarter of 2021. · Net income for the third quarter of 2022 was $224.1 million, compared to a net lo
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730430/000110465922113204/0001104659-22-113204-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.